Clinical trials: 5-FU
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma
- Trial name
- NCT05564403
- Testing
- Binimetinib, Biopsy Procedure, Biospecimen Collection
- Where
- 207 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
Identifying Novel Variants in the DPYD Gene in Patients of Non-Western Descent
This is a observational, multicenter study to identify novel variants of the DPYD gene which are possible deleterious in patients of non-Western descent.
- Trial name
- DPYD-NOW (NCT04300361)
- Testing
- Sequencing of DPYD gene
- Volunteers
- 600 people
- Sponsor
- Leiden University Medical Center
Nasopharyngeal Neoplasms
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
The present study will be a randomized, control, multicenter phase III study of recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and cisplatin regimen (GP) or 5-Fluorouracil…
- Trial name
- NCT01528618
- Testing
- gemcitabine and cisplatin, 5-Fluorouracil and cisplatin
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
This trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT)…
- Trial name
- 1-BETTER (NCT04825288)
- Testing
- Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- XBiotech, Inc.
Colorectal Cancer
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced…
- Trial name
- NCT07474727
- Testing
- AMT-676, 5-FU, Leucovorin
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Multitude Therapeutics Inc.
Biliary Tract Cancer
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
FOLFIRI as a salvage treatment in metastatic biliary tract cancer (BTC) patients who failed gemcitabine containing chemotherapy
- Trial name
- NCT03110510
- Testing
- Fluorouracil, Irinotecan Hydrochloride, leucovorin calcium
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) followed Surgery for locally advanced adenocarcinoma of esophagogastric junction
- Conditions
- Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy, Pembrolizumab
- Trial name
- KEYSTONE-003 (NCT04813523)
- Testing
- Pembrolizumab Injection [Keytruda]
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07059611
- Testing
- RP2, 5-Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer
Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer
The purpose of the study is to evaluate the efficacy and safety of the capecitabine or 5-fluorouracil selection, according to polymorphisms in TS-3'UTR and ERCC1-118, to be combined with oxaliplatin or irinotecan as first-line…
- Trial name
- SETICC (NCT01071655)
- Testing
- BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX, BVZ+XELOX
- Where
- Spain
- Volunteers
- 195 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Malignant Solid Tumor
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese participants.
- Trial name
- NCT06057038
- Testing
- GEN1042, Pembrolizumab, Cisplatin
- Where
- 3 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Genmab
Gastric Cancer
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Background: Gastric (stomach) cancer is a rare cancer. In most cases, by the time it has been diagnosed it has spread to other organs in the body and the chance of a cure is very small.
- Trial name
- NCT00941655
- Testing
- Oxaliplatin, Irinotecan, 5-Fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma of Esophagus
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
The purpose of this study is to improve their outcome by either changing the chemotherapy drugs or giving them radiation therapy with concurrent chemotherapy, hoping that this will improve their outcome.
- Trial name
- NCT01608464
- Testing
- irinotecan and docetaxel, Cisplatin, fluorouracil and concurrent radiation therapy
- Where
- Saudi Arabia
- Volunteers
- 170 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Primary Rectal Cancer
Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer
Trial compares two preoperative stage II and III rectal cancer treatment strategies: short term radiotherapy 5x5 Gy and delayed surgery after 6 weeks versus conventional chemoradiotherapy 50 Gy + 5Fu/Lv and surgery also after 6…
- Trial name
- NCT00597311
- Testing
- radiotherapy
- Where
- Lithuania
- Volunteers
- 150 people
- Sponsor
- Kaunas University of Medicine
HNSCC
Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
The aim of the trial is to study the efficacy of adding concomitant chemotherapy (carboplatin/5FU) to Erbitux-radiotherapy in patients with locally advanced head and neck cancer.
- Trial name
- 2007-01 (NCT00609284)
- Testing
- cetuximab, Carboplatin, 5FU concomitant, Radiotherapy
- Where
- 5 sites in France
- Volunteers
- 406 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Common Warts
Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart
Warts caused by the human papillomavirus (HPV) are one of the most common skin conditions among children. The prevalence of warts in school-aged children ranges from 10 to 20 percent.
- Trial name
- NCT06737406
- Testing
- Topical 5% fluorouracil cream, Topical 0.005% calcipotriol ointment
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Mazandaran University of Medical Sciences
Colorectal Cancer, Liver Metastases
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis of RAS wildtype.
- Trial name
- NCT03493048
- Testing
- Irinotecan, Cetuximab, 5-fluorouracil
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Sun Yat-sen University
Colo-rectal Cancer
FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.
This study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab/cetuximab) as…
- Trial name
- NCT07515963
- Testing
- FULIRI combination targeted therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhongnan Hospital
HIV Infections, Cervix, Dysplasia
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women
To determine the efficacy and safety of intravaginal fluorouracil administered as prophylaxis in HIV-infected women who have received standard ablative therapy (surgery) for high-grade cervical dysplasia (pre-cancer of the…
- Trial name
- NCT00000758
- Testing
- Fluorouracil
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 158 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Colorectal Cancer
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
The ONTOP study is a prospective, single-arm, open-label phase II clinical trial. A total of 32 patients with advanced MSS/pMMR colorectal cancer who have failed first-line treatment will receive second-line standard treatment…
- Trial name
- ONTOP (NCT07106034)
- Testing
- Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Pudong Hospital
Squamous Cell Carcinoma of Head and Neck
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants…
- Trial name
- OrigAMI-5 (NCT07276399)
- Testing
- Amivantamab, Pembrolizumab, Carboplatin
- Where
- 203 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.